Jefferies Raises Price Target on Exact Sciences (EXAS) as HEDIS Includes Cologuard in Quality Measures
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Exact Sciences (EXAS) Confirms Inclusion of Cologuard in HEDIS Quality Measures
October 3, 2016 12:36 PM EDTExact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS.
... More
Exact Sciences (EXAS) Gains as NCQA Updates Colorectal Cancer Screening Measure
October 3, 2016 12:09 PM EDTExact Sciences (NASDAQ: EXAS) gains as NCQA updates colorectal cancer screening measure.
From NCQA:
The National Committee for Quality Assurance (NCQA) has updated the HEDIS®Colorectal Cancer Screening measure in order to respond to recently revised scientific guidelines by the US Preventive... More